Albumin Octapharma: Uses, Dosage & Side Effects

What Is Albumin Octapharma and What Is It Used For?

Albumin Octapharma 50 g/l contains human albumin, the most abundant protein in blood plasma, constituting approximately 60% of the total protein content of plasma. Albumin is produced naturally by the liver and fulfills several vital physiological functions: it maintains the oncotic (colloid osmotic) pressure that keeps fluid within the blood vessels, serves as a carrier protein for hormones, enzymes, fatty acids, bilirubin, and numerous medications, and functions as a free radical scavenger providing antioxidant protection to the body. The product is manufactured by Octapharma AB from pooled human plasma collected from carefully screened and tested donors.

As a plasma substitute belonging to the pharmacotherapeutic group of plasma protein fractions, Albumin Octapharma is specifically designed to replace the albumin that has been lost through bleeding, burns, surgical procedures, or various medical conditions that result in hypoalbuminemia (abnormally low albumin levels in the blood). When administered intravenously, the albumin molecules exert an oncotic effect that draws water from the interstitial space into the intravascular compartment, thereby expanding the circulating blood volume and helping to maintain adequate organ perfusion and tissue oxygenation throughout the body.

The solution is clear and slightly viscous, appearing nearly colorless to yellow, amber, or green in color. These color variations are entirely normal and do not indicate any quality issue. Each 100 ml of solution contains 5 grams of total protein, of which at least 95% consists of human albumin. The product is a sterile preparation intended exclusively for intravenous administration in healthcare facilities equipped to monitor patients receiving blood-derived products.

Human albumin solutions, including Albumin Octapharma, are listed on the WHO Model List of Essential Medicines, underscoring their critical importance in global healthcare. They are among the most frequently used plasma-derived medicinal products in intensive care units, surgical departments, emergency medicine, hepatology, and nephrology services worldwide. The decision to use albumin rather than alternative volume expanders, such as crystalloid solutions or synthetic colloids, as well as the specific dose required, is determined by the treating physician based on the patient's overall clinical condition, laboratory values, and hemodynamic parameters.

Clinical Indications

Albumin Octapharma is indicated for the restoration and maintenance of circulating blood volume in a variety of clinical scenarios where volume replacement is deemed necessary and the use of a colloid solution is considered appropriate by the treating physician. The primary clinical indications include:

• Hypovolemia: Acute blood volume loss resulting from hemorrhage, major trauma, extensive surgery, or severe burns where crystalloid solutions alone are insufficient to maintain adequate circulation and organ perfusion.
• Hypoalbuminemia in critical illness: Severely ill patients in intensive care settings who develop dangerously low albumin levels that contribute to pathological fluid shifts, tissue edema, and organ dysfunction.
• Liver cirrhosis with ascites: Patients undergoing large-volume paracentesis (therapeutic drainage of ascitic fluid from the abdomen) require albumin replacement to prevent post-paracentesis circulatory dysfunction, a potentially serious complication.
• Nephrotic syndrome: Severe cases characterized by massive proteinuria and significant edema unresponsive to diuretic therapy may benefit from albumin infusion to temporarily improve intravascular volume and facilitate diuresis.
• Therapeutic plasma exchange: Albumin is the most commonly used replacement fluid during plasmapheresis procedures, maintaining oncotic pressure while the patient's own plasma is being exchanged.
• Cardiopulmonary bypass surgery: Albumin may be used as a priming solution for the bypass circuit and for post-operative volume management in patients undergoing open-heart surgery.
• Neonatal hyperbilirubinemia: In severe cases of newborn jaundice, albumin infusion may be used adjunctively during exchange transfusion to enhance bilirubin binding and facilitate its removal from the circulation.

What Should You Know Before Receiving Albumin Octapharma?

Contraindications

The primary contraindication for Albumin Octapharma is a known allergy (hypersensitivity) to human albumin preparations or to any of the excipients contained in the formulation. Allergic reactions to albumin products are rare but can be clinically significant when they do occur. If you have previously experienced an allergic or anaphylactic reaction to any human albumin product, regardless of the manufacturer, you must inform your healthcare team immediately, as the use of Albumin Octapharma would be contraindicated in this situation.

While albumin is derived from human plasma, cross-reactivity between different manufacturers' albumin products is possible because the albumin protein itself is the same. Patients with a documented history of allergic reactions to any plasma-derived product should be monitored with particular vigilance during albumin infusion. The treating physician must weigh the clinical benefit against the risk of allergic reaction in each individual case.

Warnings and Precautions

Before starting an infusion of Albumin Octapharma, your treating physician will carefully evaluate your medical condition and determine whether albumin is the most appropriate therapeutic option. Several pre-existing conditions require heightened caution and more frequent monitoring during albumin administration. You should inform your doctor if you have any of the following conditions:

• Decompensated heart failure: Albumin infusion increases circulating blood volume, which can worsen cardiac function in patients with decompensated heart failure by increasing preload and the workload on an already compromised heart. Fluid overload may precipitate pulmonary edema.
• Hypertension (high blood pressure): The volume-expanding effect of albumin may further elevate blood pressure, potentially leading to hypertensive emergencies including stroke, cardiac events, or end-organ damage.
• Esophageal varices: Patients with dilated veins in the esophagus, commonly associated with portal hypertension in liver cirrhosis, face an increased risk of variceal bleeding when intravascular volume is rapidly expanded.
• Pulmonary edema: Adding volume to the circulation can exacerbate fluid accumulation in the lungs, further compromising respiratory function and potentially precipitating respiratory failure requiring mechanical ventilation.
• Hemorrhagic diathesis: Patients with bleeding tendencies require careful volume management, as rapid intravascular volume expansion can dilute circulating clotting factors and worsen coagulopathy.
• Severe anemia: A significant deficiency of red blood cells means that adequate oxygen delivery to tissues may remain compromised even with volume expansion. Albumin does not carry oxygen and cannot substitute for red blood cell transfusion in anemic patients.
• Renal anuria: Patients with absent or severely reduced urine production cannot excrete the additional fluid and sodium delivered with albumin, creating a substantial risk of severe fluid overload and its associated complications.

For traceability purposes, it is strongly recommended that the product name and batch number of Albumin Octapharma be documented each time it is administered to a patient. This practice enables tracking of the specific product used, which is critically important in the unlikely event that a safety concern is identified with a particular manufacturing batch. Your healthcare facility will maintain these records as a routine part of standard clinical practice and pharmacovigilance.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, suspect you may be pregnant, or are planning to become pregnant, inform your physician before receiving Albumin Octapharma. Human albumin is a naturally occurring protein component of blood, and its use during pregnancy and lactation should be determined by your physician based on careful assessment of clinical necessity. The physician will weigh the potential benefits of albumin replacement against any theoretical risks to determine whether treatment is appropriate for your specific clinical situation.

Clinical experience with the use of human albumin products during pregnancy is extensive, as albumin has been used in obstetric emergencies, pre-eclampsia management, and critical care settings for many decades. There are no specific reproductive toxicity concerns associated with human albumin itself, as it is an endogenous protein present naturally in the blood of all individuals. The albumin molecule crosses the placental barrier under normal physiological conditions. Nevertheless, the decision to administer any blood-derived product during pregnancy requires individualized medical judgment that accounts for both maternal and fetal well-being.

Sodium Content

How Does Albumin Octapharma Interact with Other Drugs?

Human albumin is an endogenous protein that circulates naturally in the blood, and extensive clinical experience over many decades has not identified specific harmful pharmacological interactions between albumin infusion products and other medications. Unlike many synthetic pharmaceutical agents, albumin does not undergo hepatic metabolism through cytochrome P450 enzymes or other drug-metabolizing pathways that commonly mediate drug-drug interactions in clinical practice.

However, several important clinical considerations apply when albumin is administered alongside other treatments in the hospital setting:

Compatibility Restrictions

Albumin solutions have strict compatibility requirements that must be carefully observed to ensure patient safety and maintain product efficacy. Mixing albumin with incompatible substances can cause protein denaturation, aggregation, or precipitation, rendering the product ineffective and potentially harmful:

Protein Binding Considerations

Albumin is the most abundant protein in blood plasma and serves as the primary binding protein for numerous drugs and endogenous substances. When serum albumin levels change significantly—either through disease processes that reduce albumin production or through therapeutic albumin infusion that increases circulating levels—the free (pharmacologically active) fraction of highly protein-bound drugs may be substantially altered. This pharmacokinetic consideration is particularly relevant for drugs with narrow therapeutic indices that are extensively bound to albumin, such as warfarin, phenytoin, valproic acid, diazepam, and certain non-steroidal anti-inflammatory drugs. Your treating physician and clinical pharmacist will monitor drug levels and therapeutic effects accordingly to ensure safe and effective dosing.

Coagulation Factor Dilution

When large volumes of albumin are administered for volume replacement, there is a clinically important potential for dilution of circulating coagulation factors, fibrinogen, platelets, and other essential blood components. This phenomenon, known as dilutional coagulopathy, can increase bleeding risk, particularly in patients who are already at risk due to ongoing surgical procedures, major trauma, or underlying coagulation disorders. Appropriate replacement of other blood components, including coagulation factors, fresh frozen plasma, cryoprecipitate, electrolytes, and platelet concentrates, must be ensured when clinically significant volumes of albumin are administered. Regular monitoring of coagulation parameters (PT, aPTT, fibrinogen, platelet count) is essential in these situations.

What Is the Correct Dosage of Albumin Octapharma?

Unlike many medications with predetermined dosing schedules, the administration of Albumin Octapharma is completely individualized to each patient. Your treating physician will determine the appropriate dose, concentration, infusion rate, and duration of treatment based on your specific clinical needs and physiological response to the infusion. Throughout the administration, your medical team will perform close and continuous monitoring of your condition, including regular measurement of blood pressure, heart rate, central venous pressure (where applicable), respiratory status, peripheral oxygen saturation, and urine output. Blood samples will be obtained at appropriate intervals to assess serum albumin levels, electrolyte balance, hematocrit, hemoglobin, and coagulation parameters.

Adults

Children

Elderly Patients

Elderly patients frequently have reduced cardiac reserve, diminished renal function, and decreased vascular compliance, making them particularly susceptible to fluid overload and its cardiovascular consequences during albumin infusion. While no specific dose adjustment is formally defined for geriatric patients, clinical practice guidelines recommend that the infusion rate should generally be slower and hemodynamic monitoring more frequent in older adults. The treating physician will carefully assess the patient's cardiovascular status, renal function, and fluid balance before, during, and after the infusion, adjusting both the rate and the total volume administered as necessary to prevent circulatory overload and its potentially serious complications.

Overdose

If hypervolemia develops, the standard clinical management approach includes immediate cessation of the albumin infusion, elevation of the head of the bed to reduce venous return, administration of diuretics if clinically appropriate, and comprehensive supportive care to manage the excess intravascular volume. In severe cases where pulmonary edema develops, oxygen supplementation and potentially mechanical ventilation may become necessary. There is no specific pharmacological antidote for albumin overdose; management is entirely supportive and directed toward treating the hemodynamic consequences of volume overload and preventing end-organ damage.

What Are the Side Effects of Albumin Octapharma?

Like all medicines, Albumin Octapharma can cause side effects, although not every patient who receives it will experience them. The majority of patients tolerate albumin infusions well when they are administered at the appropriate rate and under proper medical supervision by experienced healthcare professionals. However, as with any product derived from human blood, hypersensitivity reactions remain a possibility and must be recognized and treated promptly as a medical emergency.

If you experience any symptoms such as difficulty breathing, facial or throat swelling, widespread rash or hives, a rapid drop in blood pressure, dizziness, palpitations, or a feeling of impending doom during or shortly after an albumin infusion, alert your healthcare team immediately. The infusion will be stopped without delay and appropriate emergency treatment will be initiated.

When to Seek Immediate Medical Attention

Because Albumin Octapharma is administered in a controlled hospital environment, your healthcare team will be monitoring you continuously throughout the infusion. However, it is essential that you communicate any unusual sensations, discomfort, or symptoms immediately. The following symptoms require urgent medical assessment and may necessitate stopping the infusion:

• Sudden difficulty breathing, wheezing, or a feeling of throat tightness
• Swelling of the face, lips, tongue, or throat
• Severe skin rash, hives, or widespread itching
• Feeling faint, dizzy, or lightheaded
• Rapid, irregular, or pounding heartbeat
• Chest pain, pressure, or tightness
• Severe headache developing during or shortly after the infusion
• Significantly reduced or completely absent urine output
• Sudden swelling of the ankles, feet, or legs

Reporting Side Effects

Reporting suspected adverse reactions after a medicine has been authorized is important for the ongoing monitoring of its benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected side effects to their national pharmacovigilance authority. In Europe, reports can be submitted through the EMA's EudraVigilance system. In the United States, the FDA MedWatch program accepts voluntary reports. In the United Kingdom, the MHRA Yellow Card Scheme serves this purpose. These reports contribute valuable safety data that helps regulatory authorities identify emerging safety signals and take appropriate protective actions when necessary.

How Should You Store Albumin Octapharma?

Proper storage of Albumin Octapharma is essential for maintaining the quality, safety, and therapeutic efficacy of the product. In hospital settings, the pharmacy department is responsible for ensuring that correct storage conditions are maintained at all times, but understanding these requirements helps ensure that the product is handled appropriately throughout the entire supply chain from receipt to patient administration. The following storage and handling guidelines apply:

• Temperature: Store at or below 25°C (77°F). The product should be kept at a consistent temperature within this range. While brief temperature excursions during transport may be acceptable per validated stability data, prolonged exposure to elevated temperatures can cause irreversible degradation of the albumin protein and compromise product quality.
• Freezing: Albumin Octapharma must not be frozen under any circumstances. Freezing causes irreversible denaturation and aggregation of the albumin protein, rendering the product unsafe for clinical use and potentially causing serious adverse reactions if administered to a patient.
• Light protection: Keep the container in its outer carton at all times until ready for use to protect the solution from light exposure, which can accelerate oxidative protein degradation over time and affect product quality.
• After opening: The contents should be used immediately once the container has been opened (punctured). Any unused solution remaining after the infusion must be discarded appropriately according to institutional waste disposal protocols. The product does not contain antimicrobial preservatives, so there is a significant risk of microbial contamination if an opened container is stored for later use.
• Expiry date: Always check the expiry date printed on the label and outer carton before use. The expiry date refers to the last day of the month indicated. Under no circumstances should the product be used after this date has passed.
• Visual inspection: Before administration, visually inspect the solution carefully. Do not use Albumin Octapharma if the solution appears turbid or cloudy, contains visible particles, sediment, or flocculent material, or if the container seal is broken or shows evidence of tampering. Any such changes may indicate protein instability, degradation, or microbial contamination.

Keep all medicines out of the sight and reach of children. Although Albumin Octapharma is a hospital-administered product handled exclusively by healthcare professionals, standard pharmaceutical storage precautions and good distribution practices apply within all healthcare facilities.

What Does Albumin Octapharma Contain?

Active Ingredient

The active substance in Albumin Octapharma 50 g/l is human albumin. Each 100 ml of solution contains a total of 5 grams of protein, of which at least 95% consists of human albumin. The albumin is derived from pooled human plasma collected from carefully screened voluntary blood donors and processed through validated fractionation, purification, and virus inactivation methods that comply with European Pharmacopoeia standards and regulatory requirements.

Albumin is the most abundant protein in normal human plasma, typically present at concentrations of 35 to 50 g/l in healthy individuals. It is a single-chain polypeptide consisting of 585 amino acid residues, with a molecular weight of approximately 66,500 daltons (66.5 kDa). The protein is highly water-soluble, carrying a net negative charge at physiological pH, and is responsible for approximately 80% of the total colloid osmotic pressure of blood. Albumin has a biological half-life of approximately 19 days in the circulation, with a daily turnover rate of about 5% under normal physiological conditions.

Inactive Ingredients (Excipients)

Packaging and Appearance

Albumin Octapharma 50 g/l is supplied as a clear, slightly viscous solution that may appear nearly colorless, yellow, amber, or green in color. These color variations are entirely normal and reflect the natural characteristics of human albumin; they do not indicate any deficiency in product quality or safety. The solution is provided in sealed containers for single use only. Any unused solution remaining after the container has been opened must be discarded in accordance with institutional protocols for the disposal of blood-derived pharmaceutical products.

The total sodium ion content of the solution is approximately 130 to 160 mmol/l, which represents a clinically significant sodium load. This is an important consideration for patients on sodium-restricted diets, those with conditions exacerbated by sodium retention (such as congestive heart failure, renal insufficiency, or hepatic cirrhosis), and in the overall fluid and electrolyte management of critically ill patients.

What Should Healthcare Professionals Know About Administering Albumin Octapharma?

The following information is intended for healthcare professionals who are involved in the preparation, handling, and administration of Albumin Octapharma. Strict adherence to proper technique and these clinical guidelines is essential for ensuring patient safety and optimal therapeutic efficacy.

Preparation and Administration

• Route of administration: Albumin Octapharma 50 g/l is administered exclusively by the intravenous route through direct infusion.
• Dilution restrictions: The product must not be diluted with water for injection under any circumstances, as this creates a hypotonic environment that can cause hemolysis in the recipient. If dilution is clinically necessary for a specific indication, only appropriate isotonic solutions (such as 0.9% sodium chloride or 5% dextrose) should be used as directed by institutional protocols and manufacturer guidelines.
• Container integrity: Before use, verify that the container seal is intact and has not been compromised. Discard the product immediately if the seal is broken, the container shows evidence of damage, or there are any signs of leakage or tampering.
• Visual inspection: The solution should appear clear and slightly viscous, with a color ranging from nearly colorless to yellow, amber, or green. Do not use solutions that are turbid, cloudy, or contain visible precipitate, particles, or foreign matter, as these findings may indicate protein instability or microbial contamination.
• Infusion set: Use a sterile, pyrogen-free, single-use infusion set equipped with an appropriate in-line filter. Before inserting the infusion spike through the container closure, disinfect the puncture site with an appropriate antiseptic agent following institutional infection control protocols.
• Timing: Begin the infusion promptly after connecting the infusion set to the container. Any remaining unused solution must be discarded after the infusion is complete or if the infusion is discontinued.
• Temperature: When large volumes are to be administered, the product should be warmed to room temperature (approximately 20–25°C) or body temperature (37°C) before infusion to improve patient comfort, reduce the risk of hypothermia, and minimize the potential for cardiac arrhythmias associated with rapid infusion of cold fluids.

Monitoring Requirements

Patients receiving albumin infusion require close and systematic monitoring of the following clinical and laboratory parameters throughout the administration and for an appropriate period afterward:

• Blood pressure, heart rate, and respiratory rate measured at regular intervals (typically every 15 minutes during the initial phase of infusion)
• Central venous pressure (CVP) monitoring where available, particularly for critically ill patients in intensive care settings
• Urine output measurement to assess adequacy of renal perfusion and detect early signs of fluid overload or renal dysfunction
• Serum albumin levels, electrolyte panel (particularly sodium and potassium), hematocrit, hemoglobin, and coagulation parameters (PT, aPTT, fibrinogen) at appropriate intervals
• Clinical signs and symptoms of circulatory overload, including new or worsening headache, dyspnea, jugular venous distension, pulmonary crackles, peripheral edema, or rising blood pressure
• Signs of allergic or anaphylactic reactions, with enhanced vigilance during the first 15 to 30 minutes of infusion when the risk of acute hypersensitivity is highest

When albumin preparations are administered in clinically significant volumes, adequate hydration of the patient must be ensured and maintained. The infusion rate should be individualized based on the specific clinical circumstances, indication, and the patient's cardiovascular reserve. During therapeutic plasma exchange procedures, the albumin infusion rate should be coordinated with the rate of plasma removal to maintain hemodynamic stability.

Appropriate concurrent replacement of other essential blood components, including coagulation factors, fresh frozen plasma, cryoprecipitate, electrolytes, and platelet concentrates, must be maintained when clinically indicated. For batch traceability and pharmacovigilance purposes, the product name and batch number should be thoroughly documented in the patient's medical record each time Albumin Octapharma is administered.